Abstract
Background
Epsilon aminocaproic acid (EACA) has been used in the past to prevent cerebral aneurysm rerupture. Recent studies have indicated that short-term treatment with EACA can lower rebleeding rates without significantly increasing ischemic or thrombotic complications or permanent shunt rates. The goal of this study is to determine the efficacy of EACA in the prevention of aneurysm rerupture at a high volume subarachnoid hemorrhage center.
Methods
We conducted a retrospective study of 355 consecutive subarachnoid hemorrhage patients over a 2-year period under our current protocol for EACA use. Patients were divided by presentation time to our institution and whether the patient received EACA. The primary endpoints of the study were rebleeding rates, ischemic complications, thrombotic complications, vasospasm, shunt rates, and outcomes.
Results
Rerupture rates were reduced by half in the entire pool of patients on EACA after controlling for Hunt and Hess Scores and Fisher Scores. In patients who received early aneurysm treatment, this effect persisted but was non-statistically significant due to the small numbers of reruptures. In addition, there was no evidence to suggest that EACA increased ischemic or thrombotic complications, vasospasm, or VPS rates. In patients presenting earlier than 24 h to our institution, there was a non-significant trend toward worse outcomes after EACA use. This trend was reversed in patients arriving after 24 h.
Conclusion
There is evidence to suggest that EACA is protective from aneurysm rerupture without significant ischemic or thrombotic complications when used for less than 72 h. However, if the aneurysm is treated, this effect is modest indicating that early aneurysm treatment remains the gold standard for rerupture prevention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Inagawa T, Kamiya K, Ogasawara H, Yano T. Rebleeding of ruptured intracranial aneurysms in the acute stage. Surg Neurol. 1987;28(2):93–9.
Beck J, Raabe A, Szelenyi A, et al. Sentinel headache and the risk of rebleeding after aneurysmal subarachnoid hemorrhage. Stroke. 2006;37(11):2733–7.
Kassell NF, Torner JC, Adams HP Jr. Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the Cooperative Aneurysm Study. J Neurosurg. 1984;61(2):225–30.
Roos Y, Rinkel G, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a cochrane review. Stroke. 2003;34(9):2308–9.
Lindsay KW. Antifibrinolytic agents in subarachnoid haemorrhage. J Neurol. 1987;234(1):1–8.
Wijdicks EF, Hasan D, Lindsay KW, et al. Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage. Stroke. 1989;20(12):1674–9.
Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9):2617–21.
Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97(4):771–8.
Harrigan MR, Rajneesh KF, Ardelt AA, Fisher WS III. Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus. Neurosurgery. 2010;67(4):935–9; discussion 939–940.
Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The International cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg. 1990;73(1):18–36.
Rosenwasser RH, Buchheit WA, Truex RC, Jr. Management of subarachnoid hemorrhage. Pa Med. 1984;87(12):72, 74, 76.
Hijdra A, Braakman R, van Gijn J, Vermeulen M, van Crevel H. Aneurysmal subarachnoid hemorrhage. Complications and outcome in a hospital population. Stroke. 1987;18(6):1061–7.
Juvela S. Rebleeding from ruptured intracranial aneurysms. Surg Neurol. 1989;32(5):323–6.
Nishioka H, Torner JC, Graf CJ, Kassell NF, Sahs AL, Goettler LC. Cooperative study of intracranial aneurysms and subarachnoid hemorrhage: a long-term prognostic study. III. Subarachnoid hemorrhage of undetermined etiology. Arch Neurol. 1984;41(11):1147–51.
de Gans K, Nieuwkamp DJ, Rinkel GJ, Algra A. Timing of aneurysm surgery in subarachnoid hemorrhage: a systematic review of the literature. Neurosurgery. 2002;50(2):336–40; discussion 340–332.
Milhorat TH, Krautheim M. Results of early and delayed operations for ruptured intracranial aneurysms in two series of 100 consecutive patients. Surg Neurol. 1986;26(2):123–8.
Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International cooperative study on the timing of aneurysm surgery. Part 2: surgical results. J Neurosurg. 1990;73(1):37–47.
Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg. 1997;86(2):220–5.
Acknowledgments
No funding was received or used in the making of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schuette, A.J., Hui, F.K., Obuchowski, N.A. et al. An Examination of Aneurysm Rerupture Rates with Epsilon Aminocaproic Acid. Neurocrit Care 19, 48–55 (2013). https://doi.org/10.1007/s12028-012-9735-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-012-9735-8